التفاصيل البيبلوغرافية
| العنوان: |
Teclistamab for relapsed refractory multiple myeloma patients on dialysis. |
| المؤلفون: |
Lebreton, P., Lachenal, F., Bouillie, S., Pica, G. M., Aftisse, H., Pascal, L., Montes, L., Macro, M., Johnson, N., Harel, S., Fernandez, M., De Renzis, B., Lioure, B., Lazareth, A., Javelot, M., Louni, C., Huart, A., Perrot, A. |
| المصدر: |
British Journal of Haematology; Nov2024, Vol. 205 Issue 5, p2077-2079, 3p |
| مصطلحات موضوعية: |
CYTOKINE release syndrome, COVID-19, BISPECIFIC antibodies, GLOMERULAR filtration rate, EXTRAMEDULLARY diseases |
| مستخلص: |
The article discusses the use of teclistamab, a humanized immunoglobulin bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) who are on dialysis. The study, conducted in France, included 15 dialysis-dependent RRMM patients who were treated with teclistamab. The results showed promising responses in most patients, with manageable side effects such as cytokine release syndrome and infections. The study suggests that teclistamab monotherapy could be a feasible and safe option for patients with dialysis-dependent RRMM who are typically excluded from clinical trials. [Extracted from the article] |
|
Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |